Sitosterolemia Metabolism (STAIR7002)

University of Manitoba

Status: Completed

Conditions: Sitosterolemia

Treatments: Drug: Ezetimibe

Study type: Interventional

Funder types: Other

Identifiers

NCT01584206

B2011:051

Details and patient eligibility

About

Ezetimibe has become the treatment choice for patients with sitosterolemia. Ezetimibe is an inhibitor of cholesterol absorption from the gastrointestinal tract. The purpose of this study is to determine if ezetimibe improves whole body plant sterol and cholesterol homeostasis.

Enrollment: 8 patients

Sex: All

Ages: 16 to 99 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• confirmed diagnosis of homozygous sitosterolemia as established by genotyping and clinical parameters

Exclusion criteria

• pregnant
• intellectual disability
• major infectious diseases
• immunodeficiency
• cancer
• renal failure
• diabetes

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

Ezetimibe

Experimental group

Description:

Compare on and off ezetimibe

Treatment:

Drug: Ezetimibe